Pricing Log in Create free account

IRulya Therapeutics Inc. (IRLA) vs Promis Neurosciences (PMN)

IRulya Therapeutics Inc. and Promis Neurosciences are both Biotechnology companies. IRulya Therapeutics Inc. and Promis Neurosciences are of similar size ($32.7M and $29.8M). Across the 7 metrics below, IRulya Therapeutics Inc. leads on 6 and Promis Neurosciences on 1.

Valuation

Metric IRLA PMN Biotechnology median
P/E n/m n/m 10.60
P/S n/m 16,913.44 9.40
P/B n/m 0.75 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.28 0.66
EV/Sales n/m (5,572.97) 9.02
Earnings yield (463.25%) (324.53%) (32.88%)
Free cash flow yield (25.09%) (113.16%) (23.13%)

Profitability

Metric IRLA PMN Biotechnology median
Gross margin 0.00% 0.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 784.09% (172.30%) (51.96%)
Return on assets (76.68%) (127.57%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric IRLA PMN Biotechnology median
Revenue growth (TTM) — 450.00% 6.76%
EPS growth (last fiscal year) (28.24%) (922.18%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IRLA PMN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 14.52 7.85 4.97
Net debt to EBITDA 0.00 0.15 1.01

Dividend

Metric IRLA PMN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric IRLA PMN Biotechnology median
Market cap 29.81m 32.74m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack